Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing-remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide

被引：52

作者：

Ichikawa, M

Koh, CS

Inoue, A

Tsuyusaki, J

Yamazaki, M

Inaba, Y

Sekiguchi, Y

Itoh, M

Yagita, H

Komiyama, A

机构：

[1] Shinshu Univ, Sch Med, Dept Med Neurol, Matsumoto, Nagano 3908621, Japan

[2] Shinshu Univ, Sch Med, Dept Pediat, Matsumoto, Nagano 3908621, Japan

[3] Shinshu Univ, Sch Med, Dept Pathol, Matsumoto, Nagano 3908621, Japan

[4] Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2000年 / 102卷 / 01期

关键词：

myelin oligodendrocyte glycoprotein; experimental autoimmune encephalomyelitis; IL-12; multiple sclerosis;

D O I：

10.1016/S0165-5728(99)00153-8

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Treatment with monoclonal anti-IL-12 antibody injected on day 0, 7 and 10 after immunization with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55 in NOD mice resulted in significant suppression of the development and the severity of the chronic relapsing-remitting experimental autoimmune encephalomyelitis (EAE) both clinically and histologically. The spleen cells from anti-IL-12 antibody treated mice displayed markedly inhibited MOG(35-55) specific proliferation and IFN-gamma production. MOG(35-55) specific antibody production was enhanced by anti-IL-12 antibody treatment. These results suggest that IL-12 is critically involved in the pathogenesis of MOG-induced EAE and that antibody to IL-12 could be an effective therapeutic agent in the clinical treatment of autoimmune demyelinating diseases such as multiple sclerosis (MS). (C) 2000 Elsevier Science B.V. All rights reserved.

引用

页码：56 / 66

页数：11

共 46 条

[1] Myelin oligodendrocyte glycoprotein: A novel candidate autoantigen in multiple sclerosis [J].